Results 11 to 20 of about 15,380 (223)

Pre-Emptive Amlodipine for FOLFIRINOX-Induced Hypertensive Crises Without Primary Hypertension: A Novel Chronotherapeutic Strategy. [PDF]

Clin Case Rep
ABSTRACT FOLFIRINOX remains a cornerstone therapy for advanced pancreatic ductal adenocarcinoma (PDAC), but its toxicity profile extends beyond myelosuppression and neuropathy to include even rarer complications such as treatment‐associated hypertension.
Pustake M, Wells-Gatnik W, Shukla V, Corral J, Gaur S.   +4 more
europepmc   +2 more sources

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study). [PDF]

Int J Cancer
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group.   +19 more
europepmc   +2 more sources

Circulating mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

Therapeutic Advances in Medical Oncology, 2021
Background: Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progression
Fleur van der Sijde, Zakia Azmani, Marc G. Besselink, Bert A. Bonsing, Jan Willem B. de Groot, Bas Groot Koerkamp, Brigitte C. M. Haberkorn, Marjolein Y. V. Homs, Wilfred F. J. van IJcken, Quisette P. Janssen, Martijn P. Lolkema, Saskia A. C. Luelmo, Leonie J. M. Mekenkamp, Dana A. M. Mustafa, Ron H. N. van Schaik, Johanna W. Wilmink, Eveline E. Vietsch, Casper H. J. van Eijck   +17 more
doaj   +1 more source

A bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer [PDF]

, 2014
© 2014 Chan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited ...
AJ Sutton, C Louvet, D Cunningham, D Li, DC Hoglin, DD Von Hoff, DG Altman, Doug Coyle, E Poplin, F Di Costanzo, G Colucci, G Colucci, H Ueno, HA Burris 3rd, Henry Lam, JD Berlin, Jonathan R. Brody, JP Higgins, Kelly Lien, Kelvin Chan, Keya Shah, M Ozaka, MH Kulke, MJ Moore, MK Parmar, PA Philip, PF Peddi, R Herrmann, R Warsame, S Boeck, T Conroy, T Li, V Heinemann, W Scheithauer, X Wang, Y Nakai, Yoo-Joung Ko   +36 more
core   +9 more sources

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

World Journal of Surgical Oncology, 2021
Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care. Here, we report the efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in the ...
Beilei Zhang, Fengyan Zhou, Jiaze Hong, Derry Minyao Ng, Tong Yang, Xinyu Zhou, Jieyin Jin, Feifei Zhou, Ping Chen, Yunbao Xu   +9 more
doaj   +1 more source

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

Case Reports in Oncology, 2020
Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal treatment.
Garry Ceccon, Michael Wollring, Anna Brunn, Martina Deckert, Dirk Waldschmidt, Gereon R. Fink, Norbert Galldiks   +6 more
doaj   +1 more source

Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis

Therapeutic Advances in Medical Oncology, 2023
Background: FOLFIRINOX, used in metastatic pancreatic cancer (MPC), is highly efficacious but also toxic. Various dose modifications for FOLFIRINOX have been introduced to reduce toxicity.
Kwangrok Jung, Suhyun Choi, Hyunjoo Song, Kyuhan Kwak, Soyeon Anh, Jae Hyup Jung, Bomi Kim, Jinwoo Ahn, Jaihwan Kim, Jin-Hyeok Hwang, Jong-chan Lee   +10 more
doaj   +1 more source

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

BMC Cancer, 2021
Background Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC).
Jiayuan Chen, Qingling Hua, Haihong Wang, Dejun Zhang, Lei Zhao, Dandan Yu, Guoliang Pi, Tao Zhang, Zhenyu Lin   +8 more
doaj   +1 more source

Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results

Исследования и практика в медицине, 2023
Purpose. To study the efficacy and safety of total neoadjuvant chemotherapy (NACT) with the FOLFIRINOX regimen for locally advanced gastric (GC) and cardioesophageal junction (CEJ) cancer.Patients and methods.
M. V. Sedova, M. A. Batov, A. A. Kolomeytseva, V. M. Khomyakov, N. N. Volchenko, A. A. Fedenko   +5 more
doaj   +1 more source

The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro

Scientific Reports, 2021
Cholangiocarcinoma (CCA) is a rare biliary tract cancer with a low five-year survival rate and high recurrence rate after surgical resection. Currently treatment approaches include systemic chemotherapeutics such as FOLFIRINOX, a chemotherapy regimen is ...
Olivia Jones, Xiaoqian Cheng, Saravana R. K. Murthy, Lawan Ly, Taisen Zhuang, Giacomo Basadonna, Michael Keidar, Jerome Canady   +7 more
doaj   +1 more source